

Regimen Reference Order – oBINutuzumab desensitization

oBINutuzumab desensitization protocol is prescribed in combination with a oBINutuzumab-based protocol
 To order this therapy in ARIA, refer to Additional Information below

Planned Course: Refer to prescribed oBINutuzumab-based protocol

Indication for Use: Eligible patients with previous hypersensitivity reactions to oBINutuzumab

Alert: Desensitization protocol

oBINutuzumab:

- *oBINutuzumab is prepared in 1 bag to a final concentration of 1 mg/mL by Pharmacy*
- *oBINutuzumab must be the first chemotherapy agent administered when given in combination with another chemotherapy agent*
- *IV tubing is primed with oBINutuzumab*
- *oBINutuzumab is administered slowly following specified rate increases*
- *oBINutuzumab infusion can take up to 5 hours to complete*

CVAD: At Provider’s Discretion

Proceed with treatment if:

- ❖ *Refer to prescribed oBINutuzumab-based protocol*

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements		
Drug	Dose	CCMB Administration Guideline
montelukast	10 mg	Orally once daily in the morning starting 2 days prior to desensitization *Nursing Alert: Notify physician if patient has not taken montelukast (Self-administered at home)
Refer to prescribed oBINutuzumab-based protocol for additional pre-treatment requirements		

Treatment Regimen – oBINutuzumab desensitization

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
cetirizine	20 mg	Orally 1 hour prior to oBINutuzumab
acetaminophen	975 mg	Orally 1 hour prior to oBINutuzumab
montelukast	10mg	Orally 1 hour prior to oBINutuzumab
acetylsalicylic acid	650 mg	Orally 1 hour prior to oBINutuzumab
dexamethasone	40 mg	IV in normal saline 50 mL over 15 minutes 1 hour prior to oBINutuzumab <i>*Nursing Alert: oBINutuzumab starts 1 hour after completion of dexamethasone infusion</i>

Wait 1 hour after completion of IV pre-medication(s) before starting oBINutuzumab

oBINutuzumab	1000 mg	IV in 1000mL normal saline made up to a final concentration of 1 mg/mL following the administration rates below: Step 1: 2 mL/hour for 15 minutes, then Step 2: 4 mL/hour 15 minutes, then Step 3: 8 mL/hour for 15 minutes, then Step 4: 10 mL/hour 15 minutes, then Step 5: 20 mL/hour for 15 minutes, then Step 6: 40 mL/hour for 15 minutes, then Step 7: 80 mL/hour for 15 minutes, then Step 8: 160 mL/hour for 15 minutes, then Step 9: 200 mL/hour for 15 minutes, then Step 10: 250 mL/hour for 15 minutes, then Step 11: 300 mL/hour for 15 minutes, then Step 12: 400 mL/hour until infusion is complete <i>*Alert: Pharmacy to ensure final volume on label</i> <i>*Alert: oBINutuzumab must be the first agent administered when given in combination with another chemotherapy agent</i> <i>*Nursing Alert: IV tubing is primed with oBINutuzumab</i> <i>*Nursing Alert: There is no interruption in oBINutuzumab infusion unless patient is experiencing an infusion-related reaction</i>
--------------	---------	--

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) prior to each oBINutuzumab infusion and as clinically indicated
- No observation period is required. Patient can be discharged from treatment room if stable whether they have had a reaction or not
- Refer to the prescribed oBINutuzumab-based protocol for additional monitoring

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
<i>Refer to the prescribed oBINutuzumab-based protocol</i>		

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Refer to the prescribed oBINutuzumab-based protocol for additional discharge instructions

ADDITIONAL INFORMATION

- Once the patient requires oBINutuzumab desensitization protocol, all subsequent **oBINutuzumab doses must be given using oBINutuzumab desensitization protocol**
- Hematologist must write first prescription of oBINutuzumab desensitization protocol
- Administering nurse must document any infusion-related reactions with any dose of oBINutuzumab
- Refer to the prescribed oBINutuzumab-based protocol for additional oBINutuzumab information
- **ARIA ordering:** Support protocol is available under **oBINutuzumab** in the “Desensitization” folder
- Administration site restrictions may be in place for oBINutuzumab desensitization